These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 7562759)

  • 21. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inter- and Intra-Observer Reliability of Modified Rodnan Skin Score Assessment in Thai Systemic Sclerosis Patients: A Validation for Multicenter Scleroderma Cohort Study.
    Foocharoen C; Thinkhamrop B; Mahakkanukrauh A; Suwannaroj S; Netwijitpan S; Sripavatakul K; Chuealee W; Boottam B; Towiwat P; Seubmee P; Daungkum K; Kongpan D; Mangkala J; Nanagara R
    J Med Assoc Thai; 2015 Nov; 98(11):1082-8. PubMed ID: 26817178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of relationship between functional ability and skin score in patients with systemic sclerosis.
    Herrick A; Rooney B; Finn J; Silman A
    J Rheumatol; 2001 Feb; 28(2):292-5. PubMed ID: 11246664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.
    Shand L; Lunt M; Nihtyanova S; Hoseini M; Silman A; Black CM; Denton CP
    Arthritis Rheum; 2007 Jul; 56(7):2422-31. PubMed ID: 17599771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
    Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
    Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
    Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
    Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computerized measurement of magnetic resonance imaging erosion volumes in patients with rheumatoid arthritis: a comparison with existing magnetic resonance imaging scoring systems and standard clinical outcome measures.
    Bird P; Lassere M; Shnier R; Edmonds J
    Arthritis Rheum; 2003 Mar; 48(3):614-24. PubMed ID: 12632412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-assessment of skin tightness severity by scleroderma patients.
    Daungkum K; Foocharoen C; Mahakkanukrauh A; Suwannaroj S; Thinkhamrop B; Nanagara R
    Int J Rheum Dis; 2016 Oct; 19(10):989-995. PubMed ID: 27126197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ventricular late potentials in systemic sclerosis: relationship with skin involvement.
    Paradiso M; Di Franco M; Musca A; Basili S; Riccieri V; Paoletti V; De Matteis A; Mammarella A
    J Rheumatol; 2002 Jul; 29(7):1388-92. PubMed ID: 12136893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated teaching courses of the modified Rodnan skin score in systemic sclerosis.
    Ionescu R; Rednic S; Damjanov N; Varjú C; Nagy Z; Minier T; Czirják L
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S37-41. PubMed ID: 20576212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
    Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR; Feldman BM; Pope JE; Tomlinson GA
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appearance self-esteem in systemic sclerosis--subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables.
    van Lankveld WG; Vonk MC; Teunissen H; van den Hoogen FH
    Rheumatology (Oxford); 2007 May; 46(5):872-6. PubMed ID: 17308314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis.
    Allanore Y; Borderie D; Lemaréchal H; Cherruau B; Ekindjian OG; Kahan A
    J Rheumatol; 2003 Jan; 30(1):68-73. PubMed ID: 12508392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie).
    Tiev KP; Diot E; Clerson P; Dupuis-Siméon F; Hachulla E; Hatron PY; Constans J; Cirstéa D; Farge-Bancel D; Carpentier PH
    J Rheumatol; 2009 Jul; 36(7):1470-6. PubMed ID: 19487271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plasmapheresis therapy in systemic sclerosis].
    Szúcs G; Szamosi S; Aleksza M; Veres K; Soltész P
    Orv Hetil; 2003 Nov; 144(45):2213-7. PubMed ID: 14686006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.